The company in question is, Biogen Inc. (NASDAQ:BIIB) currently with a stock price of 303.5 (-0.33% today). The market cap for Biogen Inc. is 66496.85, and is in the sector Healthcare, and Biotechnology industry. The target price for Biogen Inc. is 344.61. Currently Biogen Inc. is trading with a P/E of 17.72, and a forward P/E of 14.57. Average volume for Biogen Inc. is 1859.84 and so far today it is 1104800.
Performance in the last year for Biogen Inc. has been -3.55%. For EPS growth, Biogen Inc. has seen a growth of 24.00%, and is looking to grow in the next year to 3.67%. More long term stats show that EPS growth has been 31.30% over the last five years and could be 8.57% for the next five years. Biogen Inc. has seen sales growth quarter over quarter at 11.70%, with EPS growth quarter over quarter at 21.60%. The 20-day simple moving average is 2.05%, with the 200-day simple moving average coming to 10.37%.
Since the IPO date for Biogen Inc. on the 9/17/1991, Biogen Inc. has seen performance year to date to be -0.93%. With Biogen Inc. trading at 303.5, the dividend yield is *TBA, and the EPS is 17.13.
So could Biogen Inc., be undervalued? Well as said before P/E is 17.72. The PEG is 2.07, P/S is 5.92 and the P/B is at 5.83. The P/cash is 17.51, with P/free cash flow at 20.68.
Biogen Inc. ability to deal with debt shows that the current ratio is 3, and the quick ratio is 2.6. This is with long term debt/equity at 0.57, and total debt/equity at 0.57.
In terms of margins, Biogen Inc. has a gross margin of 88.20%, an operating margin of 47.90% and a profit margin of 34.00%.Payout ratio for Biogen Inc. is 0.00%. Return on assets come to 18.50% with return on investment coming to 23.50%.
Insider ownership for Biogen Inc., is at 0.10% and institutional ownership comes to 88.30%. Outstanding shares are at 219.1. While shares float is 218.5. The float short is currently 0.99%, and short ratio is 1.16.